Feeds:
Posts
Comments

Posts Tagged ‘neuroscience’


Two postdoc positions are available in my lab.

Both are part of the larger, European Commission-funded FET-Open programme, ArrestAD, which has recently been funded.

Position 1 aims to characterise heparin-binding proteins in Alzhiemer’s disease.

Position 2 aims to develop inhibitors to Golgi sulfotransferases.

For both positions, feel free to contact me directly by e-mail for informal discussions.

Read Full Post »


ArrestAD

The ArrestAD team had its kick off meeting in Paris on 5 January 2017. This was held on Paris, the base of our coordinator, Dulcé Papy-Garcia and was hosted by the APHP in the Espace Scipion. Team members from outside Paris stayed at the Hotel La Demeure  situated nearby and though on the Boulevard St Marcel, nice and quiet.

The kick off meeting started with a presentation form our coordinator, which provided the backdrop for the day. Science presentations from the participants then followed. These provided an overview of the position of the field of the participant and then summarised research plans. In a multidisciplinary project, one cannot be fully up to speed with the other fields, so we all learned a lot. The more technical part of these presentations gave us an opportunity to discus the nuts and bolts of our research plans and how these fitted together. It…

View original post 115 more words

Read Full Post »


David Paramelle’s paper on using gold nanoparticles stoichiometrically functionalised with a peptide that recognises sphingolipids has just been published in Advanced Healthcare Materials (Publisher’s site; Pubmed)

The paper is the classic “Sunday afternoon” project, which arose through discussions with Rachel Kraut at NTU.

As ever, a lot more than Sunday afternoons ended up being put into the paper, because David had to develop some new approaches. Particularly nice was the purification of nanoparticles functionalised with the sphingomyelin-binding peptide (called “SBD”) from non-functionalised nanoparticles. This is a key step for the preparation of nanoparticles carrying just one functional peptide or group. Hitherto, we have happily had affinity tags as the functional group, which allows for affinity chromatography (examples here, here and here). (more…)

Read Full Post »


The Fibroblast Growth Factor Gordon Research conference is biennial, so it almost follows a Martian calendar and next year it will be five years old. The fifth Gordon Research conference on Fibroblast Growth Factors will be held in Ventura, California, March 1-7 2014. This is THE meeting for all things FGF and assembles an eclectic mix of leaders in the field, young PIs, industry scientists and scientists in training. A Gordon Research Seminar will precede the full meeting. This was introduced at the last GRC (May 2012) and was very successful. (more…)

Read Full Post »


Two recent retractions on Retraction Watch merit more than a passing mention, because they demonstrate, yet again, the wildly different and completely contradictory reactions of individuals and journals to data that turn out to be problematic. In one sense this is an update post on “Chalk and Cheese“, “Re-use of “stripes”“, “Correct correction?” and “Data re-use warrants correction at PNAS“. (more…)

Read Full Post »


LT1 at 1 pm
Prof Dave Allsop from Lancaster University will give a seminar entitled “Protein oligomers as toxins, biomarkers and molecular targets for neurodegenerative disease”

Buffet lunch will be available in the Committee Room from 12 noon.

The formation of fibrillar aggregates from a range of different proteins is a common feature of numerous different ‘protein conformational’ diseases. In these diseases, normally soluble proteins are deposited in the form of insoluble fibrils inside and/or outside of cells. In the systemic amyloidoses, extracellular fibrillar deposits (often called amyloid) can be found in many different tissues and organs throughout the body. Localised deposits are found in some other diseases, such as late-onset diabetes, where they are restricted to the pancreas, and some important neurodegenerative diseases, where they are often found only in the brain. Examples of the latter include Alzheimer’s disease, Parkinson’s disease, the prion diseases (e.g. CJD in humans), Huntington’s disease, frontotemporal dementia and motor neuron disease. David’s  research is concerned with the pathological role of these misfolded proteins, and is focussed mainly on neurodegenerative disease and late-onset (type 2) diabetes.

Read Full Post »